Cargando…

In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials

RNA–protein interactions are crucial for diverse biological processes. In prokaryotes, RNA–protein interactions enable adaptive immunity through CRISPR-Cas systems. These defence systems utilize CRISPR RNA (crRNA) templates acquired from past infections to destroy foreign genetic elements through cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ho-min, Park, Yunseol, Berani, Urta, Bang, Eunkyu, Vankerschaver, Joris, Van Messem, Arnout, De Neve, Wesley, Shim, Hyunjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547417/
https://www.ncbi.nlm.nih.gov/pubmed/36207756
http://dx.doi.org/10.1186/s13062-022-00339-5
_version_ 1784805260918784000
author Park, Ho-min
Park, Yunseol
Berani, Urta
Bang, Eunkyu
Vankerschaver, Joris
Van Messem, Arnout
De Neve, Wesley
Shim, Hyunjin
author_facet Park, Ho-min
Park, Yunseol
Berani, Urta
Bang, Eunkyu
Vankerschaver, Joris
Van Messem, Arnout
De Neve, Wesley
Shim, Hyunjin
author_sort Park, Ho-min
collection PubMed
description RNA–protein interactions are crucial for diverse biological processes. In prokaryotes, RNA–protein interactions enable adaptive immunity through CRISPR-Cas systems. These defence systems utilize CRISPR RNA (crRNA) templates acquired from past infections to destroy foreign genetic elements through crRNA-mediated nuclease activities of Cas proteins. Thanks to the programmability and specificity of CRISPR-Cas systems, CRISPR-based antimicrobials have the potential to be repurposed as new types of antibiotics. Unlike traditional antibiotics, these CRISPR-based antimicrobials can be designed to target specific bacteria and minimize detrimental effects on the human microbiome during antibacterial therapy. In this study, we explore the potential of CRISPR-based antimicrobials by optimizing the RNA–protein interactions of crRNAs and Cas13 proteins. CRISPR-Cas13 systems are unique as they degrade specific foreign RNAs using the crRNA template, which leads to non-specific RNase activities and cell cycle arrest. We show that a high proportion of the Cas13 systems have no colocalized CRISPR arrays, and the lack of direct association between crRNAs and Cas proteins may result in suboptimal RNA–protein interactions in the current tools. Here, we investigate the RNA–protein interactions of the Cas13-based systems by curating the validation dataset of Cas13 protein and CRISPR repeat pairs that are experimentally validated to interact, and the candidate dataset of CRISPR repeats that reside on the same genome as the currently known Cas13 proteins. To find optimal CRISPR-Cas13 interactions, we first validate the 3-D structure prediction of crRNAs based on their experimental structures. Next, we test a number of RNA–protein interaction programs to optimize the in silico docking of crRNAs with the Cas13 proteins. From this optimized pipeline, we find a number of candidate crRNAs that have comparable or better in silico docking with the Cas13 proteins of the current tools. This study fully automatizes the in silico optimization of RNA–protein interactions as an efficient preliminary step for designing effective CRISPR-Cas13-based antimicrobials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13062-022-00339-5.
format Online
Article
Text
id pubmed-9547417
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95474172022-10-09 In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials Park, Ho-min Park, Yunseol Berani, Urta Bang, Eunkyu Vankerschaver, Joris Van Messem, Arnout De Neve, Wesley Shim, Hyunjin Biol Direct Research RNA–protein interactions are crucial for diverse biological processes. In prokaryotes, RNA–protein interactions enable adaptive immunity through CRISPR-Cas systems. These defence systems utilize CRISPR RNA (crRNA) templates acquired from past infections to destroy foreign genetic elements through crRNA-mediated nuclease activities of Cas proteins. Thanks to the programmability and specificity of CRISPR-Cas systems, CRISPR-based antimicrobials have the potential to be repurposed as new types of antibiotics. Unlike traditional antibiotics, these CRISPR-based antimicrobials can be designed to target specific bacteria and minimize detrimental effects on the human microbiome during antibacterial therapy. In this study, we explore the potential of CRISPR-based antimicrobials by optimizing the RNA–protein interactions of crRNAs and Cas13 proteins. CRISPR-Cas13 systems are unique as they degrade specific foreign RNAs using the crRNA template, which leads to non-specific RNase activities and cell cycle arrest. We show that a high proportion of the Cas13 systems have no colocalized CRISPR arrays, and the lack of direct association between crRNAs and Cas proteins may result in suboptimal RNA–protein interactions in the current tools. Here, we investigate the RNA–protein interactions of the Cas13-based systems by curating the validation dataset of Cas13 protein and CRISPR repeat pairs that are experimentally validated to interact, and the candidate dataset of CRISPR repeats that reside on the same genome as the currently known Cas13 proteins. To find optimal CRISPR-Cas13 interactions, we first validate the 3-D structure prediction of crRNAs based on their experimental structures. Next, we test a number of RNA–protein interaction programs to optimize the in silico docking of crRNAs with the Cas13 proteins. From this optimized pipeline, we find a number of candidate crRNAs that have comparable or better in silico docking with the Cas13 proteins of the current tools. This study fully automatizes the in silico optimization of RNA–protein interactions as an efficient preliminary step for designing effective CRISPR-Cas13-based antimicrobials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13062-022-00339-5. BioMed Central 2022-10-07 /pmc/articles/PMC9547417/ /pubmed/36207756 http://dx.doi.org/10.1186/s13062-022-00339-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Park, Ho-min
Park, Yunseol
Berani, Urta
Bang, Eunkyu
Vankerschaver, Joris
Van Messem, Arnout
De Neve, Wesley
Shim, Hyunjin
In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials
title In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials
title_full In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials
title_fullStr In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials
title_full_unstemmed In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials
title_short In silico optimization of RNA–protein interactions for CRISPR-Cas13-based antimicrobials
title_sort in silico optimization of rna–protein interactions for crispr-cas13-based antimicrobials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547417/
https://www.ncbi.nlm.nih.gov/pubmed/36207756
http://dx.doi.org/10.1186/s13062-022-00339-5
work_keys_str_mv AT parkhomin insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT parkyunseol insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT beraniurta insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT bangeunkyu insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT vankerschaverjoris insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT vanmessemarnout insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT denevewesley insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials
AT shimhyunjin insilicooptimizationofrnaproteininteractionsforcrisprcas13basedantimicrobials